diagnost tool
biomed devic servic
diagnost tool
thought ahead busi week five name keep
eye gh
ahead key healthcar confer next week expect flurri updat
includ pre-announc earli guid major busi updat
highlight thought gh
expect in-lin print rel estim
roughli match midpoint ilmn guid rev adj ep
vs street import guid think
may guid revenu growth slightli ahead
like face lowest comp year growth assum
hit midpoint guid compar prior year lack visibl
forward growth rate primarili driven uncertainti relat
pace popul genom project think highlight next monday
new product announc mileston target may achiev near
long term unansw investor question includ year deliv
genom statu dtc genet market
expect comment termin merger agreement
recent develop commerci agreement privat held
archerdx view posit look meaning move clinic
research applic rais pt
deliv modest beat six-quart trail averag
consid headwind transitori reiter view
growth engin intact mark first quarter partial contribut
genom health first time comp partial contribut
see upsid stand-alone compani revenu estim
y/i in-lin volum y/ q/q believ
may comment combin exas-ghdx guid time well inclin
publish pro forma estim expect greater clariti guid
earn call expect addit updat regard cologuard blue-c
expect pre-announc result guid prior
call howev believ may reveal volum growth
investor present wednesday estim y/i impli
volum growth expect discuss recent announc
bespok studi progress within four oncolog channel includ
buildout direct oncolog sale forc opportun transplant follow
decemb final lcd posit ntra announc week
exit contract signatera oncolog revenu pharma
guid contract revenu
gh dont expect gh pre-announc result expect compani
provid updat relat recent final pan-canc coverag
initi enrol prospect eclips trial
fda submiss statu program reiter
gh focu idea believ catalyst-rich may help gh exceed
street top-lin growth estim year
expect solid print rev vs street
turn solid year y/i growth posit readthrough qdel
preliminari beat last night like driven strong flu sale cdc data support
view expect wait guid call expect
provid updat regard launch three fda-clear bcid panel
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research iii best author
analyst knowledg she/h receipt materi non-publ inform issuer
analyst employ outsid us regist research analyst finra analyst may associ
person canaccord genuiti llc therefor may subject finra rule nyse rule restrict
commun subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin januari et
date time product januari et
pt use multipl unchang cologuard revenu estim discount back two
year discount rate
pt gh use premium multipl revenu estim million discount back year
price target genmark use multipl revenu estim discount back year
pt use multipl ep
pt use multipl revenu estim discount back two year discount rate
risk achiev target price valuat
risk model includ number new physician add per quarter physician re-ord rate level
 spend cologuard re-ord year first cologuard user due re-screen
pama pama establish medicar price base weight median commerci payor rate pama present
expect go effect januari though time could push opinion view risk
small none given view pama rate like remain similar present medicar rate
competit mani compani develop colorect screen modal particularli blood test liquid biopsi
compani includ grail name three test like fobt fecal occult blood test
fecal immunochem test use year mani new test offer cancer detect uncertain
competit develop test proven pre-canc claim
reimburs pursu health plan coverag privat commerci payor assur health plan
elect cover cologuard uncertainti price might reimburs test
note typic medic technolog risk risk includ commerci execut sale market team regulatori
risk fda potenti product recal patent infring product liabil lawsuit anti-trust litig
commerci execut season ebb flow involv direct sell primari care physician gi
assur abl meet exceed guidanc provid quarter-to-quart
premium valuat gh trade premium multipl rel mani diagnost compani given gh best class liquid
biopsi portfolio huge believ valuat warrant bad news regulatori reimburs time product
launch shortfal financi could result lower move stock
diagnost tool
risk obtain fda approv flagship test pan-canc label current
ldt gh take assay fda expedit access pathway via breakthrough devic design
eap design expect give prioriti review access senior fda offici doesnt guarante approv guardant
view fda approv signific mileston need facilit commerci adopt extend approv timelin would
pose risk project
risk obtain pan-canc medicar coverag today gh medicar coverag nsclc
guardant expect obtain pan-canc medicar coverag base expect fda approv guardant expect
nation coverag determin ncd test delay obtain pan-canc coverag would limit compani
opportun revenu
risk obtain fda approv guardantomni guardant recent launch guardant omni research use intend
take guardantomni fda obtain fda approv delay time rel expect could limit
compani opportun revenu
manag execut risk given technic natur develop liquid biopsi gh commerci success depend
manag abil launch new panel secur addit reimburs regulatori new label win
provid guidanc shortfal rel guid mark materi risk
risk launch commerci compani largest market opportun gh peg market
opportun high risk individu huge opportun primarili requir strong data gh
releas promis pilot data rel small sampl size guardant experi setback poor result
delay/cancel launch gh growth potenti would significantli reduc
competit guardant compet directli compani provid comprehens genom profil therapi select
foundat medicin roch think guardant like compet recurr monitoring/residu
diseas market among other guardant may compet screen diagnost compani includ exact
scienc colorect cancer screen possibl grail launch
reimburs risk end cover live think fda approv like drive
broader payor adopt larg health insur aet other current coverag decis guardant
fail increas reimburs coverag would limit opportun
risk relat intern expans guardant offer test countri outsid establish guardant
health amea softbank facilit expans asia middl east africa engag clinic trial work japan
lack compel data regulatori setback could delay expans plan ou addit guardant could struggl facilit
adopt emerg market due pricing/reimburs test
relianc sole supplier guardant reli heavili sole sequenc provid gh activ suppli agreement
decemb automat renew thereaft contract either parti option opt
agreement notic year advanc opt gh may struggl find replac sequenc meet
risk relat oper larg grow lab san francisco bay area home earthquak san francisco bay
area prone earthquak larg earthquak could interrupt lab oper compani lab headquart redwood
risk genmark includ time commerci launch new assay content next gener instrument eplex
regulatori clearanc competit potenti reduc reimburs syndrom panel test product recal patent
infring product liabil lawsuit anti-trust litig howev believ ultim success depend upon
abil launch new fda-approv assay perform instrument platform sever key product develop
underway delay clinic trial extend timelin could affect futur revenu earn
believ key risk includ major new product launch novaseq instrument premium valuat
excess peer group risk associ demand pace novaseq placement hiseq unit
decommiss competit noise/tract though believ meaning competit risk well bay nih/
govern budgets/spend particularli foreign govern like japan genom research center regulatori
risk fda addit risk factor less concern includ typic medic technolog risk price instrument
consum risk associ move test clinic increas compani focu bioinformat
long-term also highlight spend scale helix
panorama asp compress erod margin gross margin drop sequenti
expect margin continu erod result reduct in-network price commerci payor come on-line
expand includ averag risk patient expect mitig revenu impact asp compress
drive busi profit account though busi may suffer increas test volum outpac
relianc lab partner move away lab partner priorit direct sale continu sell
number refer lab partner includ arup clarient sonic unclear durabl compani lab partnership
diagnost tool
may particularli sinc lost lab partner past certain lab choos promot anoth nipt decid offer
nipt includ recent quest
fda oversight ldt test lab-develop test ivd fda take posit author
regul test medic devic fdc act gener chosen enforc author mandat
certain ltd seek fda clearanc howev fda look regul ldt use risk-bas approach begin
deem highest-risk devic follow lower risk devic believ panorama would treat moderate-risk
high-risk among highest-risk devic fda indic high-and moderate-risk ltd market
guidelin final remain market fda review submiss expect
requir remov product market regul fda ltd remain subject uncertainti
controversi
constel addit talk fda receiv clearanc constel us fda indic
constel platform may appropri review de novo classif allow market
distribut constel us convers on-going fda requir obtain regulatori
clearanc market constel softwar diagnost purpos abl secur fda clearanc
compli on-going fda regulatori requir would unabl commerci constel compani cloud-
competit compet directli compani offer nipt carrier screen test ob/gyn mfm
market labcorp roch counsyl mani compani larger abl
leverag economi scale win busi offer multipl test servic women health one requisit form
observ research doctor often switch test brand may make market share gain difficult
futur advers impact busi
strong competit oncolog uncertain time oncolog launch develop liquid biopsi test oncolog
manag size opportun billion initi sampl collect activ lung
ovarian cancer collect dozen collabor includ vanderbilt stanford columbia cancer research
uk other also initi collect effort breast cancer plan announc collabor later year
alon pursu blood-bas test oncolog market leader today substanti base
revenu data addit player includ foundat medicin roch grail person genom diagnost genom
counsyl trovagen pathway genom mdx name hand
ethic legal social concern relat genet inform could reduc demand genet test natera
test provid dna test servic like conduct use panorama expect conduct oncolog may
rais ethic legal social issu regard privaci appropri use result inform government author
could social purpos limit regul use genom inform genom test prohibit test genet
predisposit certain condit particularli known cure similarli concern may lead patient
refus use genet test even permiss ethic social concern may also complic abil protect patent
import medicaid nipt approxim birth unit state state medicaid program recipi
end recogn medicaid provid state state requir compani oper lab
state becom recogn medicaid provid typic medicaid rate price medicar commonli lowest
payor term dollar
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
relev issuer
diagnost tool
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
current past month client canaccord genuiti
affili compani period canaccord genuiti affili compani provid invest bank servic exact
scienc
past month canaccord genuiti affili compani receiv compens invest bank servic
past month canaccord genuiti affili compani lead manag co-lead manag co-
manag public offer secur publicli disclos offer secur
relat deriv
canaccord genuiti one affili compani market maker liquid provid secur
relat deriv
canaccord genuiti one affili compani intend seek expect receiv compens invest
bank servic next three month
analyst visit materi oper payment receiv relat
rate histori
rate histori
diagnost tool
rate histori
guardant health rate histori
rate histori
diagnost tool
line articl mifid ii deleg regul disclos price perform preced five year
whole period financi instrument offer invest servic provid less five year pleas
note price histori refer actual past perform past perform reliabl indic futur price and/or
